芪苈强心胶囊对糖尿病心肌病患者预后的影响

目的 研究芪苈强心胶囊对糖尿病心肌病患者预后的影响.方法 选择2014年10月至2016年5月在我院心内科住院的糖尿病心肌病患者72例,依据随机数字表法分为观察组和对照组,每组36例.对照组患者给予常规治疗,观察组患者在常规治疗基础上加用芪苈强心胶囊,疗程为3个月.观察两组患者入院时及治疗3个月后Ⅲ型前胶原氨基端肽(PⅢNP)、N末端B型脑钠肽原(NT-proBNP)、超敏C反应蛋白(hs-CRP)、心脏超声及再住院率方面的差异.结果 治疗后3个月,观察组和对照组患者的PⅢNP(7.5±1.5)μg/L vs(8.3±1.4)μg/L]、NT-proBNP(545.8±165.2)pg/L vs(646.3±169.2)pg/L]和hs-CRP(5.6±1.0)mg/L vs(6.4±1.6)mg/L]比较,观察组均较对照组明显下降,差异均有统计学意义(P<0.05或0.01);观察组和对照组患者治疗3个月后左室射血分数(LVEF)(52.0±3.0)%vs(49.9±2.8)%]、左室舒张末内径(LVEDD)(44.5±2.9)mm vs(46.1±2.7)mm]以及二尖瓣舒张早期血流与二尖瓣环运动速度比(E/E')(9.5±1.0)vs(10.0±0.9)]比较,差异均有统计学意义(P<0.05或0.01);观察组患者治疗3个月后再住院率为8.33%,明显低于对照组的27.78%,差异具有统计学意义(P<0.05);两组患者治疗期间未见明显药物不良反应.结论 芪苈强心胶囊可以改善糖尿病心肌病患者预后,值得临床推广应用.

Effect of Qili Qiangxin Capsule on prognosis in patients with diabetic cardiomyopathy

Objective To observe the influence of Qili Qiangxin capsule in patients with diabetic cardiomy-opathy (DCM). Methods A total of 72 patients with DCM in the Cardiology Department of Xingtai Third Hospital from October 2014 to May 2016 were divided randomly into the observation group (36 cases) and the control group (36 cases), and both groups were treated with standardized treatment. In addition to standard therapy, Qili Qiangxin capsule was received in observation group. All the cases were given treatment for three months. The serum typeⅢpro-collagen amino peptide (PⅢNP), NT-proBNP, hs-CRP concentration and rehospitalization rate were compared before treatment and three months after treatment. The left ventricular end diastolic volume (LVEDD), left ventricular systol-ic function indicator (LVEF), mitral diastolic early flow and mitral annulus velocity raito (E/E') and cardiac events were also compared. Results There were statistically significant differences of the serum PⅢNP (7.5 ± 1.5)μg/L vs (8.3±1.4)μg/L], NT-proBNP (545.8±165.2) pg/L vs (646.4±169.2) pg/L] and hs-CRP (5.6±1.0) mg/L vs (6.4±1.6) mg/L] concentration after three months treatment between the observation group and the control group (P<0.05 or 0.01). There were significant difference between two groups in LVEF (52.0 ± 3.0)%vs (49.9 ± 2.8)%], the left ventricular end diastolic volume (LVEDD) (44.5 ± 2.9) mm vs (46.1 ± 2.7) mm] and E/E' (9.5 ± 1.0) vs (10.0 ± 0.9)] (P<0.05 or 0.01). Rates of total rehospitalization (8.33%vs 27.78%) were lower in the observation group than that in the control group (P<0.05). Conclusion Qili Qiangxin capsule can improve the prognosis of patients with DCM, which is worthy of clin-ical promotion.